Can-Fite’s Veterinary Piclidenoson: A Decade of Projected Sales and Impact
Can-Fite Biopharma Ltd., an Israeli-based biotech company, has recently announced that they are projecting upfront and royalties on sales of Piclidenoson for veterinary use to reach an impressive $325 million in the aggregate over the next decade, assuming a 2029 launch. Piclidenoson, a non-steroidal anti-inflammatory drug (NSAID), has shown promising results in treating various inflammatory conditions in animals. Let’s delve deeper into this development and explore the potential implications for both individuals and the world at large.
The Impact on Individuals
For pet owners, the availability of Piclidenoson could be a game-changer. Inflammatory conditions such as arthritis, allergies, and skin diseases are common in pets, causing discomfort and sometimes even endangering their lives. With Piclidenoson’s potential ability to effectively manage these conditions, pet owners can look forward to improved quality of life for their beloved companions. Furthermore, the drug’s non-steroidal nature sets it apart from other treatments, as steroids can have adverse side effects, including weight gain, increased appetite, and potential for liver damage.
The Impact on the World
The veterinary industry as a whole stands to benefit significantly from Piclidenoson’s success. The global pet care market is projected to reach $193.35 billion by 2027, with a compound annual growth rate (CAGR) of 5.6% during the forecast period. Piclidenoson’s projected sales of $325 million over the next decade contribute to this growth, driving innovation and investment in the sector. Moreover, the drug’s potential impact extends beyond the veterinary realm, as the knowledge and technology gained from its development could be applied to human medicine.
Additional Insights
According to Can-Fite’s CEO, Dr. Pnina Fishman, Piclidenoson is currently in the final stages of development for veterinary use, with the company planning to submit regulatory filings in the U.S. and Europe in 2022. The drug has already demonstrated success in clinical trials for canine osteoarthritis, showing significant improvements in pain and inflammation reduction. Additionally, Piclidenoson is being investigated for use in feline asthma, equine osteoarthritis, and canine atopic dermatitis.
Conclusion
Can-Fite Biopharma’s Piclidenoson presents an exciting development for both the veterinary industry and pet owners, with projected sales of $325 million in the next decade. The drug’s potential to effectively manage inflammatory conditions in animals, particularly in the context of the growing pet care market, makes it an intriguing investment opportunity. Moreover, the knowledge and technology gained from Piclidenoson’s development could have far-reaching implications for human medicine. As we eagerly await regulatory approval, the anticipation for this innovative drug continues to grow.
- Can-Fite Biopharma projects Piclidenoson sales for veterinary use to reach $325 million in the next decade.
- The drug is currently in the final stages of development for veterinary use, with regulatory filings planned for 2022.
- Piclidenoson has shown significant improvements in pain and inflammation reduction in clinical trials for canine osteoarthritis.
- The drug is being investigated for use in various other inflammatory conditions in animals.
- The knowledge and technology gained from Piclidenoson’s development could have implications for human medicine.
